Search

Displaying results 4981 - 4990 of 7180 in total
  1. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  2. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  3. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).

  4. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-NC
  5. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  6. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  7. Drug

    Empasiprubart

    go.drugbank.com/drugs/DB16469
    Investigational

    Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]

  8. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  9. Drug

    CA-074 methyl ester

    go.drugbank.com/drugs/DB07223
    Experimental

    It is converted by cellular esterases to CA-074.[A258234,A258239]

    Synonyms: Methyl N-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-isoleucyl-L-prolinate, L-Proline, N-[[(2S,3S)-3-[(propylamino)carbonyl]oxiranyl]carbonyl]-L-isoleucyl-, methyl ester
  10. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.